WuXi Biologics.
Chinese pharmaceutical company
- Reports this week
- 1
- Active events
- 1
- Connections
- 22
What's happening
Active this week
One to three months ago
Gone quiet
No new reports in 90+ days-
A company aims to expand commercial reach into Latin America, with ANVISA certification validating manufacturing standards in Brazil.Some support3 reports
-
WuXi Biologics maintains operational bases in China and leverages a global CRDMO network for client support.Well supported4 reports2 developments inside
-
WuXi Biologics facility passed GMP inspection with zero critical findings, leading to EMA support for EU marketing authorization.Well supported3 reports
-
DP15 achieved GMP release in April by leveraging the global CRDMO network capabilities.Some support1 report
-
Whitehawk Therapeutics, Inc. in-licensed assets from WuXi Biologics and participated in conferences in New York City on September 3, 2025.Some support3 reports
-
WuXi Biologics, a spin-out from WuXi AppTec, was incorporated in the Cayman Islands in 2017.Some support3 reports
No events began in the chosen period. Widen it, or reset.
Around WuXi Biologics this week
News at the entities that move WuXi Biologics most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves WuXi Biologics
-
European Medicines Agency StructuralBoth the FDA and the European Medicines Agency are evaluating NervGen's lead therapeutic candidate.Moves WuXi Biologics
-
Cayman Islands StructuralA company announced findings from Grand Cayman on September 28, 2026.Moves WuXi Biologics
-
MSCI StructuralMSCI downgraded information flow criteria for Indonesia, which influences the perception of the Philippine market.Moves WuXi Biologics
-
Hong Kong OperationalAEON Credit Service (Asia) Company Limited operates within the Hong Kong market.Moves WuXi Biologics
-
Suzhou Shared contextA company is based in Shenzhen and is also involved in business in Suzhou, while the company is trading in a market.Moves WuXi Biologics
Connections
The 13 strongest of 22, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
European Medicines Agency Structural
The European Medicines Agency regulates WuXi Biologics through facility inspections and enforcement of GMP standards.
-
Cayman Islands Structural
WuXi Biologics is formally incorporated in the Cayman Islands.
-
FDA Structural
FDA formally inspects WuXi Biologics' manufacturing facilities and requires compliance for operational approval.
-
Chris Chen Structural
Chris Chen serves as the Chief Executive Officer of WuXi Biologics.
-
WuXi AppTec Structural
WuXi Biologics was founded as a spin-out and operates as a subsidiary of WuXi AppTec.
-
GMP Structural
WuXi Biologics' facility must adhere to GMP standards for operational compliance.
-
MSCI Structural
MSCI applies its formal ESG rating model and inclusion criteria to evaluate and recognize WuXi Biologics' compliance and performance.
-
Suzhou Shared context
WuXi Biologics maintains a Biosafety Testing Center within the geographical boundaries of Suzhou.
Show all 13 connections
-
Wuxi Shared context
The company is based in the location of Wuxi, providing its operational context.
-
Latin America Shared context
WuXi Biologics plans to expand its commercial operations into the Latin American market.
-
Hebei Shared context
WuXi Biologics operates a facility within the geographical boundaries of Hebei Province.
-
Jiangsu Shared context
WuXi Biologics is based in the Jiangsu province.
-
Hong Kong Operational
WuXi Biologics utilizes the Hong Kong stock exchange for filing financial results.
History
Events by the month they beganSeptember 2026
1 eventAugust 2026
1 eventJuly 2026
2 eventsShow 1 earlier month
June 2026
6 events- A company aims to expand commercial reach into Latin America, with ANVISA certification validating manufacturing standards in Brazil.
- WuXi Biologics maintains operational bases in China and leverages a global CRDMO network for client support.
- WuXi Biologics facility passed GMP inspection with zero critical findings, leading to EMA support for EU marketing authorization.
- DP15 achieved GMP release in April by leveraging the global CRDMO network capabilities.
- Whitehawk Therapeutics, Inc. in-licensed assets from WuXi Biologics and participated in conferences in New York City on September 3, 2025.
- WuXi Biologics, a spin-out from WuXi AppTec, was incorporated in the Cayman Islands in 2017.